CBD AND HUNTINGTON'S DISEASE

Cannabis and Neuropsychiatric Disorders: An Updated Review.
Chayasirisobhon S.
Acta Neurol Taiwan. 2019 Jun 15;28(2):27-39. Review.
PMID:31867704

Effects of cannabidiol (CBD) in neuropsychiatric disorders: A review of pre-clinical and clinical findings.
Elsaid S, Kloiber S, Le Foll B.
Prog Mol Biol Transl Sci. 2019;167:25-75. doi: 10.1016/bs.pmbts.2019.06.005. Epub 2019 Aug 28.
PMID:31601406

Evidence for the use of "medical marijuana" in psychiatric and neurologic disorders.
Noel C.
Ment Health Clin. 2018 Mar 23;7(1):29-38. doi: 10.9740/mhc.2017.01.029. eCollection 2017 Jan.
PMID:29955495

Free PMC Article Clinical Neurology and Epidemiology of the Major Neurodegenerative Diseases.
Erkkinen MG, Kim MO, Geschwind MD.
Cold Spring Harb Perspect Biol. 2018 Apr 2;10(4). pii: a033118. doi: 10.1101/cshperspect.a033118. Review.
PMID:28716886

Neurological Aspects of Medical Use of Cannabidiol.
Mannucci C, Navarra M, Calapai F, Spagnolo EV, Busardò FP, Cas RD, Ippolito FM, Calapai G.
CNS Neurol Disord Drug Targets. 2017;16(5):541-553. doi: 10.2174/1871527316666170413114210. Review.
PMID:28412918

Effects of a Sativex-Like Combination of Phytocannabinoids on Disease Progression in R6/2 Mice, an Experimental Model of Huntington's Disease.
Valdeolivas S, Sagredo O, Delgado M, Pozo MA, Fernández-Ruiz J.
Int J Mol Sci. 2017 Mar 23;18(4). pii: E684. doi: 10.3390/ijms18040684.
PMID:28333097

Free PMC Article Cannabinoids therapeutic use: what is our current understanding following the introduction of THC, THC:CBD oromucosal spray and others?
Maccarrone M, Maldonado R, Casas M, Henze T, Centonze D.
Expert Rev Clin Pharmacol. 2017 Apr;10(4):443-455. doi: 10.1080/17512433.2017.1292849. Epub 2017 Feb 28. Review.
PMID:28276775

Sativex-like combination of phytocannabinoids is neuroprotective in malonate-lesioned rats, an inflammatory model of Huntington's disease: role of CB1 and CB2 receptors.
Valdeolivas S, Satta V, Pertwee RG, Fernández-Ruiz J, Sagredo O.
ACS Chem Neurosci. 2012 May 16;3(5):400-6. doi: 10.1021/cn200114w. Epub 2012 Feb 9.
PMID:22860209

Free PMC Article Cannabidiol for neurodegenerative disorders: important new clinical applications for this phytocannabinoid?
Fernández-Ruiz J, Sagredo O, Pazos MR, García C, Pertwee R, Mechoulam R, Martínez-Orgado J.
Br J Clin Pharmacol. 2013 Feb;75(2):323-33. doi: 10.1111/j.1365-2125.2012.04341.x. Review.
PMID:226254. 22

Free PMC Articlec Neuroprotective effects of phytocannabinoid-based medicines in experimental models of Huntington's disease.
Sagredo O, Pazos MR, Satta V, Ramos JA, Pertwee RG, Fernández-Ruiz J.
J Neurosci Res. 2011 Sep;89(9):1509-18. doi: 10.1002/jnr.22682. Epub 2011 Jun 14.
PMID:21674569

Applause sign in Parkinsonian disorders and Huntington's disease.
Wu LJ, Sitburana O, Davidson A, Jankovic J.
Mov Disord. 2008 Dec 15;23(16):2307-11. doi: 10.1002/mds.22090.
PMID:18972544

Cannabidiol reduced the striatal atrophy caused 3-nitropropionic acid in vivo by mechanisms independent of the activation of cannabinoid, vanilloid TRPV1 and adenosine A2A receptors.
Sagredo O, Ramos JA, Decio A, Mechoulam R, Fernández-Ruiz J.
Eur J Neurosci. 2007 Aug;26(4):843-51. Epub 2007 Aug 2.
PMID:17672854

Controlled clinical trial of cannabidiol in Huntington's disease.
Consroe P, Laguna J, Allender J, Snider S, Stern L, Sandyk R, Kennedy K, Schram K.
Pharmacol Biochem Behav. 1991 Nov;40(3):701-8. PMID:1839644.